Trial Profile

A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Duvelisib (Primary) ; Venetoclax (Primary)
Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Richter's syndrome
Focus Adverse reactions; Therapeutic Use

Most Recent Events

06 Nov 2024 According to Secura Bio media release, the company will present data from this study at the upcoming 2024 American Society of Hematology (ASH) Annual Meeting taking place on December 7-10, 2024 in San Diego, CA.
31 Jul 2024 Status changed from recruiting to active, no longer recruiting.
31 Jul 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com